F-Prime's roots are in one of America’s great entrepreneurial success stories. Fidelity Investments was founded in 1946 and grew from a single mutual fund into one of the largest asset management firms in the world, with over $2 trillion in assets under management. For the last forty years, this venture capital group has had the privilege of backing other great entrepreneurs as they built ground-breaking companies in technology and life sciences, including Atari, MCI, ROLM Corp., Alibaba, Ironwood Pharmaceuticals, and Ultragenyx. Today, F-Prime's funds are larger and more global, but its teams are still small and local. F-Prime stays true to its entrepreneurial roots. In the US and Europe, F-Prime Capital Partners is investing in healthcare (formerly Fidelity Biosciences) and in technology (formerly part of Devonshire Investors). In other geographies, its sister fund is called Eight Roads (formerly Fidelity Growth Partners), with investment teams in London, Shanghai, Beijing, Hong Kong, Tokyo, and Mumbai. Together F-Prime brings a world of insight, domain expertise and relationships to support entrepreneurs. Without the pressure of fundraising from outside investors, F-Prime Capital Partners focuses all of its time finding and helping great entrepreneurs build important companies.
1upHealth operates a healthcare data platform for patients, providers, and software developers to aggregate and share medical data. 1upHealth is a way for healthcare organizations to connect, control and compute on your data. The company's platform monitors patient activity and automates secure data sharing from patients' electronic medical records and wearable device metrics within a trusted interoperability network, allowing patients to share data from disparate sources and improve healthcare outcomes.
SpectrumAi is a digital health company innovating Autism care to increase access to high-quality ABA therapy for kids on the spectrum around the world. With support from industry veterans in technology and healthcare, SpectrumAi is working with global clinical leaders in ABA therapy, parents, and payers to modernize.
Invetx is a veterinary therapeutics company that develops protein-based therapeutics for animal health. Invetx's network includes animal and human health experts, veterinary scientists, and clinicians. The company's vision is of a global animal health industry that fully leverages biopharma technologies to deliver dramatically improved health outcomes for pets and farm animal populations.
AviadoBio mission is to transform the lives of people living with neurodegenerative disorders by developing and delivering transformative gene therapies for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The Company’s technology is based on pioneering research from King’s College London and the UK Dementia Research Institute.
AppliedVR offers virtual reality-based treatments that address the complexity of chronic pain. The company's mission is to empower patients with the tools to live life, beyond chronic pain. Rooted in cognitive behavioral therapy and mindfulness, AppliedVR’s EaseVRx is the first VR-based prescription therapeutic to receive Breakthrough Device Designation by the FDA. Offering a comprehensive approach that encompasses the biological, psychological and social factors that influence how people experience chronic pain, EaseVRx enables patients to change the way they process pain and develop new, positive habits and coping skills that improve quality of life. Patients can easily self-administer EaseVRx in the comfort of their own homes, at any time, without restrictions tied to a healthcare professional’s schedule — advancing remote care as well as quality, equity and efficiency in chronic pain management.
We believe everyone should have the opportunity to live their best lives and age with dignity. That’s why we’re reinventing primary care with an approach designed to profoundly improve the healthcare and aging experience for older adults and their loved ones.
Neumora Therapeutics operates as a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience.
Burro is a developer of an autonomous farming platform for farm use and in other outdoor environments. It follows people and can autonomously run cargo around, relieving people of strenuous tasks which add little value, so that they can focus on more valuable work.
Centivo is a new type of health plan administrator that allows self-funded employers and clinicians to join forces and deliver high quality, affordable healthcare to their employees. An alternative to traditional insurance carriers or third-party administrators, Centivo offers the technology, network, claims processing, customer support, and population health management to fully administer health benefits for all or a portion of an employee population. The Centivo model emphasizes the partnership between individuals and their primary care team as the proper model to coordinate healthcare needs. Centivo’s clinical partners are dedicated to controlling costs and helping members navigate the healthcare system, aided by personalized patient/doctor matching tools. Members are rewarded for working with their primary care team and choosing high-value care and are supported through a user-friendly app and their concierge. Employers get an ally that diligently roots out waste and is accountable for performance. It was formed in 2017 and headquartered in New York, United States.
RareCyte is a life science research and diagnostic development company focused on characterizing and isolating rare cells in the blood. RareCyte is dedicated to bringing its innovative technology to the Life Sciences research, drug development, and diagnostic markets providing new tools to answer difficult questions related to cancer and cardiovascular disease. RareCyte's AccuCyte system is an open platform for the unbiased discovery and isolation of circulating tumor cells (CTCs) and circulating endothelial cells (CECs) from whole blood.
Adela develops innovative and accessible technologies focusing on the detection of cancer and other high-morbidity, high-mortality conditions through a routine blood test. Adela’s genome-wide methylome enrichment platform captures information efficiently from the entire methylome. Its technology distinguishes the most-highly informative (methylated) regions of the genome from non-informative regions and preferentially targets those regions for sequencing.
Zus Health helps a new wave of healthcare builders create technologies and services without the usual blockers. Zus Health aims to bring forth a better health reality by empowering an inspired new wave of healthcare builders to create digital technologies and services that are cheaper, easier to customize, and far more intimate. Zus Health was established in 2020 in Watertown, Massachusetts by Jonathan Bush.
Protenus harnesses the power of AI to provide healthcare organizations with scalable risk-reduction solutions that drive the safest patient outcomes while protecting the reputation of the organizations. We are committed to innovation, determined to reduce risk, and focused on supporting our community of employees, customers, and ultimately, patients. Empowering healthcare to eliminate risk is at the heart of all we do. Founded in 2014, Protenus is a three-time winner of Forbes’ America’s Best Startup Employers, is a Great Place to Work®-Certified company, and was named one of 2021 CBInsights Digital Health 150, one of The Best Places to Work in Healthcare by Modern Healthcare, and one of the Best Places to Work in Baltimore by the Baltimore Business Journal and the Baltimore Sun. Learn more at Protenus.com and follow us on Twitter @Protenus.
1upHealth operates a healthcare data platform for patients, providers, and software developers to aggregate and share medical data. 1upHealth is a way for healthcare organizations to connect, control and compute on your data. The company's platform monitors patient activity and automates secure data sharing from patients' electronic medical records and wearable device metrics within a trusted interoperability network, allowing patients to share data from disparate sources and improve healthcare outcomes.
Firefly Health provides primary health care services that redefine high-quality patient care. The company uses sophisticated technology with a thoughtful care team experience for continuous, intelligent care that changes behavior and drives value by providing virtual-first primary care approach, live video appointments with primary care physician and team for convenience without any membership fees, allowing people to make smart choices about their health, while enabling clinicians to provide unparalleled, consistent, and proactive care.
AppliedVR offers virtual reality-based treatments that address the complexity of chronic pain. The company's mission is to empower patients with the tools to live life, beyond chronic pain. Rooted in cognitive behavioral therapy and mindfulness, AppliedVR’s EaseVRx is the first VR-based prescription therapeutic to receive Breakthrough Device Designation by the FDA. Offering a comprehensive approach that encompasses the biological, psychological and social factors that influence how people experience chronic pain, EaseVRx enables patients to change the way they process pain and develop new, positive habits and coping skills that improve quality of life. Patients can easily self-administer EaseVRx in the comfort of their own homes, at any time, without restrictions tied to a healthcare professional’s schedule — advancing remote care as well as quality, equity and efficiency in chronic pain management.
Genomics plc aiming to lead the genomic transformation of healthcare, to develop and apply sophisticated analyses of massive integrated genomic and phenotypic datasets to learn about human biology and reveal the human wiring diagram They will lead the way through this challenge, using their expertise and experience to unleash the potential of genomics and set the standards by which organisations and patients can benefit from genomic data.
LakeShore Biopharma is a global, fully integrated medical company engaged in discovering, developing and commercializing innovative biotherapeutics for cancers and infectious diseases using our novel PIKA® immunomodulating technology. PIKA technology augments both innate and adaptive immune responses through the TLR3, RIG-I and MDA5 pathways. Products in clinical development include YS-ON-001 for the treatment of advanced solid tumors, YS-HBV-001 hepatitis B vaccine and the PIKA rabies vaccine for accelerated protection against rabies infection.
Cohort’s solution enables Primary Care Providers (PCP) to significantly improve the scale, efficiency and outcomes of a new or existing Chronic Care Management (CCM) program while simultaneously providing them a powerful platform for clinical trial identification and enrollment.
Hurdle offers people, couples, and families from various backgrounds care based on online mental health services. They help them match with the appropriate therapist and fill out the registration form with the objectives and therapist preferences.
J-Pharma’s mission is to help mankind by creating and developing novel pharmaceuticals based upon a human-genomic approach; an approach where people with specific diseases are treated with novel and selective agents. J-Pharma’s intellectual property (IP) embraces the notion that cell membrane transporters are tightly associated to many diseases. In addition to drug molecules that target specific transporters, J-Pharma has discovered several important drug transporters within the human body that may be used to evaluate and optimize pharmacokinetics of new drug candidates. We believe that J-Pharma’s pipelines will lead to new agents and processes (i.e. diagnostic methods) and will increase the quality of life for an ageing population in industrialized countries. J-Pharma’s overall goal is to contribute globally to the maintenance of human health and improve human welfare through the creation of new drugs.
Centivo is a new type of health plan administrator that allows self-funded employers and clinicians to join forces and deliver high quality, affordable healthcare to their employees. An alternative to traditional insurance carriers or third-party administrators, Centivo offers the technology, network, claims processing, customer support, and population health management to fully administer health benefits for all or a portion of an employee population. The Centivo model emphasizes the partnership between individuals and their primary care team as the proper model to coordinate healthcare needs. Centivo’s clinical partners are dedicated to controlling costs and helping members navigate the healthcare system, aided by personalized patient/doctor matching tools. Members are rewarded for working with their primary care team and choosing high-value care and are supported through a user-friendly app and their concierge. Employers get an ally that diligently roots out waste and is accountable for performance. It was formed in 2017 and headquartered in New York, United States.
Sana Biotechnology focuses on creating and delivering engineered cells as medicine for patients. Recent scientific advances make it possible to reprogram cells in the body or replace damaged cells and tissues, creating a new class of medicines to treat a broad array of diseases. The company is a team of scientists, clinicians and biotechnology veterans focused on creating an enduring company that makes meaningful medicines and will change the approach in treating diseases.
Verve Therapeutics is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. It has been purpose-built for the task ahead, with a team of experts in cardiovascular medicine, human genetics, gene editing, delivery technologies, drug development, and commercialization.
Checkmate Pharma is a clinical-stage biopharmaceutical company developing a new approach for cancer immunotherapy. The clinical programs are focused on enabling more people with cancer to benefit from the promise of novel immunotherapies. They leveraging their expertise in the field of CpG oligonucleotides to discover and develop immunotherapies designed to increase the efficacy of existing immunotherapies and to provide new treatment options for patients and their healthcare providers. Checkmate Pharmaceutical was founded in 2015 and is headquartered in Cambridge, Massachusetts.
PatientPing is a health technology company that is building a national network of engaged providers who are sharing information, coordinating care, and working together to get patients healthier faster. PatientPing connects healthcare providers across the country with real-time notifications and care guidelines whenever and wherever their patients receive care. PatientPing's national care coordination network includes physicians, nurses, case managers, and care coordinators across hospitals, emergency departments, accountable care organizations (ACOs), physician practices, skilled nursing facilities, home health agencies, inpatient rehabilitation centers, and payers. By connecting care teams through real-time information sharing, PatientPing enables providers to deliver higher quality and more cost-effective care, improving patient outcomes, and experience.
Devoted Health is an all-in-one healthcare company on a mission to dramatically improve the health and well-being of older Americans by caring for every person like family. To accomplish this, Devoted Health has designed and built an integrated healthcare solution that combines Devoted Health Medicare Advantage plans, access to top local providers alongside virtual and in-home care delivered by Devoted Medical, full-service guides, and world-class technology that powers it all.
Xilio Therapeutics is a biotechnology company. They offer cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. Their tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects.
Iora Health is dedicated to providing possible service and care for each patient without any of the barriers or excuses that plague the current system. They’ve completely redesigned Primary Care to help patients better manage their health and navigate the health care system. Every patient gets a personal physician as well as a personal health coach who stays in close contact during and between office visits, both of whom are available by email, text, or video in addition to in-person visits. In addition, they provide educational offerings, including group visits, to help patients stay on track with their health goals.
At WelbeHealth, we envision a world in which every human being is able to participate fully in life through their final days. We serve frail seniors through a model of comprehensive medical and social care called PACE (Program of All-Inclusive Care for the Elderly), helping our participants live better, longer, and more independently. Founded by a seasoned group of physician entrepreneurs, our leadership team hails from leading payer and provider organizations such as GoHealth Urgent Care, BAYADA Home Health, AirStrip Technologies, Evolent Health, and On Lok. With funding from leading venture capital firms, we're looking for team members who are inspired to help us deliver on our mission of unlocking the full potential of the most vulnerable seniors in our communities. Our colleagues are energized by working in diverse groups toward our shared purpose, are eager to drive groundbreaking innovations, and have the courage to care for our participants with empathy and love.
BenchSci uses AI to empower scientists to run more successful experiments to accelerate drug discovery. The company empowers scientists with advanced biomedical artificial intelligence to run more successful experiments. Backed by F-Prime, Gradient Ventures (Google’s AI fund), and Inovia Capital, BenchSci's proprietary technology accelerates science pharmaceutical companies and over 4,300 research centers worldwide.
AviadoBio mission is to transform the lives of people living with neurodegenerative disorders by developing and delivering transformative gene therapies for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The Company’s technology is based on pioneering research from King’s College London and the UK Dementia Research Institute.
Medbanks Network Technology provides data processing services to the healthcare industry. It develops an oncology database of clinical and professional medical services using information collected from hospitals. It was founded in 2014 and is based in Beijing.
Firefly Health provides primary health care services that redefine high-quality patient care. The company uses sophisticated technology with a thoughtful care team experience for continuous, intelligent care that changes behavior and drives value by providing virtual-first primary care approach, live video appointments with primary care physician and team for convenience without any membership fees, allowing people to make smart choices about their health, while enabling clinicians to provide unparalleled, consistent, and proactive care.
Protenus harnesses the power of AI to provide healthcare organizations with scalable risk-reduction solutions that drive the safest patient outcomes while protecting the reputation of the organizations. We are committed to innovation, determined to reduce risk, and focused on supporting our community of employees, customers, and ultimately, patients. Empowering healthcare to eliminate risk is at the heart of all we do. Founded in 2014, Protenus is a three-time winner of Forbes’ America’s Best Startup Employers, is a Great Place to Work®-Certified company, and was named one of 2021 CBInsights Digital Health 150, one of The Best Places to Work in Healthcare by Modern Healthcare, and one of the Best Places to Work in Baltimore by the Baltimore Business Journal and the Baltimore Sun. Learn more at Protenus.com and follow us on Twitter @Protenus.
Buoy provides a personalized all-in-one platform to help guide consumers back to health. Whether it's chatting about symptoms with Buoy Assistant to get help in the moment of sickness or researching benefits through Buoy Dashboard, Buoy is available 24/7 to help make self-diagnosis and navigating the healthcare system simple and easy. For employers, Buoy can be custom configured to surface benefits information and wellness programs, guide employees to in-network providers, and fully integrate with other health portals. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Quartet is a platform that makes it easier for people to get the best mental health care for them. The best care should fit their preferences and clinical needs, take their insurance, and link to the rest of their healthcare experience. Quartet was founded in 2014 and is based in New York, United States.
Verve Therapeutics is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. It has been purpose-built for the task ahead, with a team of experts in cardiovascular medicine, human genetics, gene editing, delivery technologies, drug development, and commercialization.
ABK Biomedical combines the clinical market with biomaterials. It specializes in improving treatment options for patients with hypervascular tumors. The company is dedicated to transforming an interventional radiology procedure called embolization.
Structure Therapeutics creates life-changing medicines for patients using advanced computational and structure-based technology. Our platform combines the latest advancements in computational chemistry, visualization of molecular interactions, and data integration to design orally available, superior medicines that overcome current limitations in biologic and peptide drugs. We are advancing our clinical-stage pipeline of differentiated, efficacious and safe treatments focused on chronic diseases with high unmet need, including cardiovascular, metabolic and pulmonary conditions. At Structure, our team’s deep experience with complex biological targets and mechanisms, structure-based drug design, and global drug discovery and development enables our bold vision: to design and develop world-class medicines with tremendous patient impact and broad commercial opportunity.
Artemis Health operates as a health data analytics company. It operates a platform that provides self-insured employers with actionable data on their benefits programs, opportunities and gaps, and tools to help them make decisions. Artemis Health's platform enables users to identify problems in their benefits’ programs; share findings with the right people; find solutions for problems and to enhance their programs; and track solutions. Dallen Allred, Dallin Regehr, and Grant Gordon founded it in 2013, with its headquarters in Salt Lake City in Utah.
Beam Therapeutics is a biotechnology company engaged in creating genetic medicines based on its base editing technology. It is pioneering the use of base editing, a potential new class of precision genetic medicines, with a vision of providing life-long cures to patients suffering from serious diseases. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the dna.
Sana Biotechnology focuses on creating and delivering engineered cells as medicine for patients. Recent scientific advances make it possible to reprogram cells in the body or replace damaged cells and tissues, creating a new class of medicines to treat a broad array of diseases. The company is a team of scientists, clinicians and biotechnology veterans focused on creating an enduring company that makes meaningful medicines and will change the approach in treating diseases.
Checkmate Pharma is a clinical-stage biopharmaceutical company developing a new approach for cancer immunotherapy. The clinical programs are focused on enabling more people with cancer to benefit from the promise of novel immunotherapies. They leveraging their expertise in the field of CpG oligonucleotides to discover and develop immunotherapies designed to increase the efficacy of existing immunotherapies and to provide new treatment options for patients and their healthcare providers. Checkmate Pharmaceutical was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Medbanks Network Technology provides data processing services to the healthcare industry. It develops an oncology database of clinical and professional medical services using information collected from hospitals. It was founded in 2014 and is based in Beijing.
Genomics plc aiming to lead the genomic transformation of healthcare, to develop and apply sophisticated analyses of massive integrated genomic and phenotypic datasets to learn about human biology and reveal the human wiring diagram They will lead the way through this challenge, using their expertise and experience to unleash the potential of genomics and set the standards by which organisations and patients can benefit from genomic data.
Avidity Biosciences, Inc. is pioneering a new class of oligonucleotide-based therapies called AOCs designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Avidity utilizes its proprietary AOC platform to design, engineer and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. Avidity's lead product candidate, AOC 1001, is designed to treat myotonic dystrophy type 1, and its four other muscle programs are focused on the treatment of muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy and Pompe disease. In addition to its muscle franchise, Avidity has development efforts focused on immune and other cell types.
Nebula Genomics is a human genome sequencing and health big data company on a mission to usher in the era of genomic sequencing by building a large and trusted genomic and health data marketplace for consumers, researchers and the medical community. Using blockchain to ensure that consumers maintain control of their data and are compensated for its use, the Nebula marketplace will aggregate a critical mass of rich genetic information that researchers can analyze in order to accelerate drug development, streamline clinical trials, and usher in the era of truly personalized medicine. The company was founded by Harvard genomics pioneer George Church, along with Harvard researchers Dennis Grishin and Kamal Obbad. Founded in 2017, Nebula Genomics has offices in San Francisco, CA and Boston, MA and is backed by investors including Khosla Ventures, Arch Venture Partners, Fenbushi Capital, Mayfield, F-Prime Capital Partners, GreatPoint Ventures, Hemi Ventures and Mirae Asset.
Xilio Therapeutics is a biotechnology company. They offer cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. Their tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects.
Centivo is a new type of health plan administrator that allows self-funded employers and clinicians to join forces and deliver high quality, affordable healthcare to their employees. An alternative to traditional insurance carriers or third-party administrators, Centivo offers the technology, network, claims processing, customer support, and population health management to fully administer health benefits for all or a portion of an employee population. The Centivo model emphasizes the partnership between individuals and their primary care team as the proper model to coordinate healthcare needs. Centivo’s clinical partners are dedicated to controlling costs and helping members navigate the healthcare system, aided by personalized patient/doctor matching tools. Members are rewarded for working with their primary care team and choosing high-value care and are supported through a user-friendly app and their concierge. Employers get an ally that diligently roots out waste and is accountable for performance. It was formed in 2017 and headquartered in New York, United States.
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, developing antibody therapeutics to treat both solid tumors and hematologic malignancies. Compass is leveraging its proprietary StitchMabs™ and common light-chain enabled multispecific platforms to empirically identify multispecifics and combinations of antibody therapeutics that can be advanced to the clinic. The company's lead product candidate, CTX-009, is a bispecific antibody, which inhibits both DLL4-mediated Notch signaling and VEGF-A signaling. CTX-009 has completed a Phase 1 dose escalation study and is in a Phase 1b study in combination with chemotherapy in patients with solid tumors. The company’s second product candidate, CTX-471, is a novel agonistic antibody of CD137, a co-stimulatory receptor on immune cells. It is currently being evaluated in a Phase 1b study in patients who were previously treated with PD-1/PD-L1 checkpoint inhibitors, and who subsequently relapsed or progressed after a period of stable disease. Compass’ third product candidate, CTX-8371, is a bispecific antibody that blocks both PD-1 and PD-L1 and is in IND-enabling studies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Sana Biotechnology focuses on creating and delivering engineered cells as medicine for patients. Recent scientific advances make it possible to reprogram cells in the body or replace damaged cells and tissues, creating a new class of medicines to treat a broad array of diseases. The company is a team of scientists, clinicians and biotechnology veterans focused on creating an enduring company that makes meaningful medicines and will change the approach in treating diseases.
At WelbeHealth, we envision a world in which every human being is able to participate fully in life through their final days. We serve frail seniors through a model of comprehensive medical and social care called PACE (Program of All-Inclusive Care for the Elderly), helping our participants live better, longer, and more independently. Founded by a seasoned group of physician entrepreneurs, our leadership team hails from leading payer and provider organizations such as GoHealth Urgent Care, BAYADA Home Health, AirStrip Technologies, Evolent Health, and On Lok. With funding from leading venture capital firms, we're looking for team members who are inspired to help us deliver on our mission of unlocking the full potential of the most vulnerable seniors in our communities. Our colleagues are energized by working in diverse groups toward our shared purpose, are eager to drive groundbreaking innovations, and have the courage to care for our participants with empathy and love.
Benchling is the modern software platform purpose-built for life science R&D. Hundreds of thousands of scientists using cutting-edge techniques like CRISPR, CAR-T immunotherapy, and genetic engineering depend on our suite of cloud applications to design DNA, collaborate on experiments, manage research workflows, and make critical R&D decisions.
Iora Health is dedicated to providing possible service and care for each patient without any of the barriers or excuses that plague the current system. They’ve completely redesigned Primary Care to help patients better manage their health and navigate the health care system. Every patient gets a personal physician as well as a personal health coach who stays in close contact during and between office visits, both of whom are available by email, text, or video in addition to in-person visits. In addition, they provide educational offerings, including group visits, to help patients stay on track with their health goals.
Beam Therapeutics is a biotechnology company engaged in creating genetic medicines based on its base editing technology. It is pioneering the use of base editing, a potential new class of precision genetic medicines, with a vision of providing life-long cures to patients suffering from serious diseases. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the dna.
Kyruus delivers proven provider search and scheduling solutions that help hospitals and health systems match patients with the providers best suited to care for them. The ProviderMatch suite of solutions—for consumers, access centers, and referral networks—enables a consistent patient experience across multiple points of access, while aligning provider supply with patient demand. The company’s proprietary provider data management platform forms the foundation of its solutions, powering them with accurate data by coupling data processing with administrative applications. Kyruus was founded in 2010 and is headquartered in Boston, Massachusetts.
Hua Medicine is a clinical-stage, innovative drug development company in China, focused on novel therapies for the treatment of diabetes and CNS disorders. Founded by pharma industry veterans and funded by a premier group of international VC investment firms such as Fidelity Asia, Fidelity Biosciences, ARCH Ventures, Venrock, SAIL and WuXi Ventures, the company has in-licensed from major pharma, world-wide rights to a potential best-in-class, oral drug for the treatment of Type 2 Diabetes which utilizes a novel mechanism of action.
Protenus harnesses the power of AI to provide healthcare organizations with scalable risk-reduction solutions that drive the safest patient outcomes while protecting the reputation of the organizations. We are committed to innovation, determined to reduce risk, and focused on supporting our community of employees, customers, and ultimately, patients. Empowering healthcare to eliminate risk is at the heart of all we do. Founded in 2014, Protenus is a three-time winner of Forbes’ America’s Best Startup Employers, is a Great Place to Work®-Certified company, and was named one of 2021 CBInsights Digital Health 150, one of The Best Places to Work in Healthcare by Modern Healthcare, and one of the Best Places to Work in Baltimore by the Baltimore Business Journal and the Baltimore Sun. Learn more at Protenus.com and follow us on Twitter @Protenus.
Quartet is a platform that makes it easier for people to get the best mental health care for them. The best care should fit their preferences and clinical needs, take their insurance, and link to the rest of their healthcare experience. Quartet was founded in 2014 and is based in New York, United States.
Biopalette is a operator of a platform intended to offer gene-editing techniques. Bio Palette plans to develop our business in three fields, classified based on the type of cells targeted for genome editing.
Nebula Genomics is a human genome sequencing and health big data company on a mission to usher in the era of genomic sequencing by building a large and trusted genomic and health data marketplace for consumers, researchers and the medical community. Using blockchain to ensure that consumers maintain control of their data and are compensated for its use, the Nebula marketplace will aggregate a critical mass of rich genetic information that researchers can analyze in order to accelerate drug development, streamline clinical trials, and usher in the era of truly personalized medicine. The company was founded by Harvard genomics pioneer George Church, along with Harvard researchers Dennis Grishin and Kamal Obbad. Founded in 2017, Nebula Genomics has offices in San Francisco, CA and Boston, MA and is backed by investors including Khosla Ventures, Arch Venture Partners, Fenbushi Capital, Mayfield, F-Prime Capital Partners, GreatPoint Ventures, Hemi Ventures and Mirae Asset.
Orchard Therapeutics is a fully integrated commercial-stage company dedicated to treating the lives of patients with rare diseases through innovative gene therapies. Orchard’s portfolio of autologous ex vivo gene therapy programs has demonstrated sustained clinical benefit in over 150 patients across five disease areas. These programs include Strimvelis®, the first autologous ex vivo gene therapy approved by the EMA in 2016, 3 programs in advanced registrational studies in MLD (metachromatic leukodystrophy), WAS (Wiskott-Aldrich syndrome), and ADA-SCID (adenosine deaminase severe combined immunodeficiency), 2 other clinical programs in X-CGD (X-linked chronic granulomatous disease) and beta-thalassemia, as well as an extensive preclinical pipeline. The company is partnered with world-leading institutions in gene therapy, including University College London, Great Ormond Street Hospital, the University of Manchester and Central Manchester University Hospitals, the University of California Los Angeles and Boston Children’s Hospital, and Telethon Institute of Gene Therapy/Ospedale San Raffaele.
Devoted Health is an all-in-one healthcare company on a mission to dramatically improve the health and well-being of older Americans by caring for every person like family. To accomplish this, Devoted Health has designed and built an integrated healthcare solution that combines Devoted Health Medicare Advantage plans, access to top local providers alongside virtual and in-home care delivered by Devoted Medical, full-service guides, and world-class technology that powers it all.
Artemis Health operates as a health data analytics company. It operates a platform that provides self-insured employers with actionable data on their benefits programs, opportunities and gaps, and tools to help them make decisions. Artemis Health's platform enables users to identify problems in their benefits’ programs; share findings with the right people; find solutions for problems and to enhance their programs; and track solutions. Dallen Allred, Dallin Regehr, and Grant Gordon founded it in 2013, with its headquarters in Salt Lake City in Utah.
Apellis Pharmaceuticals is an early-stage biotechnology company focused on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease. The company is leveraging courageous science, creativity, and compassion to deliver life-changing medicines. They aim to develop best-in-class and first-in-class therapies for a broad range of debilitating diseases that are driven by uncontrolled or excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology. It was founded in 2008 and headquartered in Waltham, Massachusetts, United States.
Buoy provides a personalized all-in-one platform to help guide consumers back to health. Whether it's chatting about symptoms with Buoy Assistant to get help in the moment of sickness or researching benefits through Buoy Dashboard, Buoy is available 24/7 to help make self-diagnosis and navigating the healthcare system simple and easy. For employers, Buoy can be custom configured to surface benefits information and wellness programs, guide employees to in-network providers, and fully integrate with other health portals. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Indalo Therapeutics is a preclinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating fibrotic diseases. Founded on groundbreaking scientific discoveries and leveraging cutting-edge insight into the molecular drivers of aberrant scarring, Indalo is harnessing the collective experience of a seasoned team of pharmaceutical scientists and executives to tackle some of the most urgent unmet medical needs in the fibrosis space.
PlasmaGen BioSciences is an Indian Bio-pharmaceutical organization specializing exclusively in Plasma Protein Therapy. Headquartered in Bangalore- India, PlasmaGen has been making every effort in the domain of Plasma product Industry and has become an Imperative one stop destination for the medical fraternity for most of the plasma products need. They have a basket of plasma products and the widest range of immunoglobulins in India catering to the requisites of various realms viz. Haematology, Oncology, Immunology, Paediatrics, Rheumatology, Dermatology and Neurology.
Protenus harnesses the power of AI to provide healthcare organizations with scalable risk-reduction solutions that drive the safest patient outcomes while protecting the reputation of the organizations. We are committed to innovation, determined to reduce risk, and focused on supporting our community of employees, customers, and ultimately, patients. Empowering healthcare to eliminate risk is at the heart of all we do. Founded in 2014, Protenus is a three-time winner of Forbes’ America’s Best Startup Employers, is a Great Place to Work®-Certified company, and was named one of 2021 CBInsights Digital Health 150, one of The Best Places to Work in Healthcare by Modern Healthcare, and one of the Best Places to Work in Baltimore by the Baltimore Business Journal and the Baltimore Sun. Learn more at Protenus.com and follow us on Twitter @Protenus.
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, developing antibody therapeutics to treat both solid tumors and hematologic malignancies. Compass is leveraging its proprietary StitchMabs™ and common light-chain enabled multispecific platforms to empirically identify multispecifics and combinations of antibody therapeutics that can be advanced to the clinic. The company's lead product candidate, CTX-009, is a bispecific antibody, which inhibits both DLL4-mediated Notch signaling and VEGF-A signaling. CTX-009 has completed a Phase 1 dose escalation study and is in a Phase 1b study in combination with chemotherapy in patients with solid tumors. The company’s second product candidate, CTX-471, is a novel agonistic antibody of CD137, a co-stimulatory receptor on immune cells. It is currently being evaluated in a Phase 1b study in patients who were previously treated with PD-1/PD-L1 checkpoint inhibitors, and who subsequently relapsed or progressed after a period of stable disease. Compass’ third product candidate, CTX-8371, is a bispecific antibody that blocks both PD-1 and PD-L1 and is in IND-enabling studies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Checkmate Pharma is a clinical-stage biopharmaceutical company developing a new approach for cancer immunotherapy. The clinical programs are focused on enabling more people with cancer to benefit from the promise of novel immunotherapies. They leveraging their expertise in the field of CpG oligonucleotides to discover and develop immunotherapies designed to increase the efficacy of existing immunotherapies and to provide new treatment options for patients and their healthcare providers. Checkmate Pharmaceutical was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Biopalette is a operator of a platform intended to offer gene-editing techniques. Bio Palette plans to develop our business in three fields, classified based on the type of cells targeted for genome editing.
Biopalette is a operator of a platform intended to offer gene-editing techniques. Bio Palette plans to develop our business in three fields, classified based on the type of cells targeted for genome editing.
At WelbeHealth, we envision a world in which every human being is able to participate fully in life through their final days. We serve frail seniors through a model of comprehensive medical and social care called PACE (Program of All-Inclusive Care for the Elderly), helping our participants live better, longer, and more independently. Founded by a seasoned group of physician entrepreneurs, our leadership team hails from leading payer and provider organizations such as GoHealth Urgent Care, BAYADA Home Health, AirStrip Technologies, Evolent Health, and On Lok. With funding from leading venture capital firms, we're looking for team members who are inspired to help us deliver on our mission of unlocking the full potential of the most vulnerable seniors in our communities. Our colleagues are energized by working in diverse groups toward our shared purpose, are eager to drive groundbreaking innovations, and have the courage to care for our participants with empathy and love.
Iora Health is dedicated to providing possible service and care for each patient without any of the barriers or excuses that plague the current system. They’ve completely redesigned Primary Care to help patients better manage their health and navigate the health care system. Every patient gets a personal physician as well as a personal health coach who stays in close contact during and between office visits, both of whom are available by email, text, or video in addition to in-person visits. In addition, they provide educational offerings, including group visits, to help patients stay on track with their health goals.
Xilio Therapeutics is a biotechnology company. They offer cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. Their tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects.
Denali Therapeutics is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, ALS and others. Denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. Denali is rigorously pursuing a science-driven approach to translational medicine and clinical development.
US HealthVest is an innovative behavioral healthcare firm that has redefined the psychiatric hospital space. De novo strategies and acquisitions of operating facilities with unrealized potential are the core of the US HealthVest business model. Each facility is structured to offer multiple service lines in order to serve the needs of specific patient population groups. The senior management team of US HealthVest has successfully built psychiatric hospital businesses which were acquired by public companies. Ascend Health was founded by Richard Kresch, M.D. in 2005 and was one of the largest private psychiatric hospital providers with nine freestanding facilities and nearly 900 beds. Ascend Health was sold to Universal Health Services (NYSE: UHS) in 2012. The predecessor company, Heartland Health Developments, also focused on psychiatric care and was sold to Psychiatric Solutions in 2004.
Caribou Biosciences is an operator of a medical technology company intended to analyze cell and genome engineering. The company specializes in cellular engineering and analysis based on the CRISPR-Cas9 technology platform which paired with a guide RNA, cuts double-stranded DNA and allows for specific changes to DNA, enabling the development of therapeutics for agricultural biotechnology, industrial biotechnology, and basic and applied biological research.
Orchard Therapeutics is a fully integrated commercial-stage company dedicated to treating the lives of patients with rare diseases through innovative gene therapies. Orchard’s portfolio of autologous ex vivo gene therapy programs has demonstrated sustained clinical benefit in over 150 patients across five disease areas. These programs include Strimvelis®, the first autologous ex vivo gene therapy approved by the EMA in 2016, 3 programs in advanced registrational studies in MLD (metachromatic leukodystrophy), WAS (Wiskott-Aldrich syndrome), and ADA-SCID (adenosine deaminase severe combined immunodeficiency), 2 other clinical programs in X-CGD (X-linked chronic granulomatous disease) and beta-thalassemia, as well as an extensive preclinical pipeline. The company is partnered with world-leading institutions in gene therapy, including University College London, Great Ormond Street Hospital, the University of Manchester and Central Manchester University Hospitals, the University of California Los Angeles and Boston Children’s Hospital, and Telethon Institute of Gene Therapy/Ospedale San Raffaele.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.